173 related articles for article (PubMed ID: 32698368)
1. Generation of Glioblastoma Patient-Derived Intracranial Xenografts for Preclinical Studies.
Kerstetter-Fogle AE; Harris PLR; Brady-Kalnay SM; Sloan AE
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698368
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
Xia S; Lal B; Tung B; Wang S; Goodwin CR; Laterra J
Neuro Oncol; 2016 Apr; 18(4):507-17. PubMed ID: 26320116
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.
Shen Y; Grisdale CJ; Islam SA; Bose P; Lever J; Zhao EY; Grinshtein N; Ma Y; Mungall AJ; Moore RA; Lun X; Senger DL; Robbins SM; Wang AY; MacIsaac JL; Kobor MS; Luchman HA; Weiss S; Chan JA; Blough MD; Kaplan DR; Cairncross JG; Marra MA; Jones SJM
Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19098-19108. PubMed ID: 31471491
[TBL] [Abstract][Full Text] [Related]
4. Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
Kiang KM; Chan AA; Leung GK
BMC Cancer; 2021 Mar; 21(1):265. PubMed ID: 33706745
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging-guided intracranial resection of glioblastoma tumors in patient-derived orthotopic xenografts leads to clinically relevant tumor recurrence.
Oudin A; Moreno-Sanchez PM; Baus V; Niclou SP; Golebiewska A
BMC Cancer; 2024 Jan; 24(1):3. PubMed ID: 38166949
[TBL] [Abstract][Full Text] [Related]
6. Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas.
Kratzsch T; Kuhn SA; Joedicke A; Hanisch UK; Vajkoczy P; Hoffmann J; Fichtner I
J Cancer Res Clin Oncol; 2018 May; 144(5):809-819. PubMed ID: 29427211
[TBL] [Abstract][Full Text] [Related]
7. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease.
Radaelli E; Ceruti R; Patton V; Russo M; Degrassi A; Croci V; Caprera F; Stortini G; Scanziani E; Pesenti E; Alzani R
Histol Histopathol; 2009 Jul; 24(7):879-91. PubMed ID: 19475534
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
9. Brain-Mimetic 3D Culture Platforms Allow Investigation of Cooperative Effects of Extracellular Matrix Features on Therapeutic Resistance in Glioblastoma.
Xiao W; Zhang R; Sohrabi A; Ehsanipour A; Sun S; Liang J; Walthers CM; Ta L; Nathanson DA; Seidlits SK
Cancer Res; 2018 Mar; 78(5):1358-1370. PubMed ID: 29282221
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models.
Jandial R; Neman J; Lim PP; Tamae D; Kowolik CM; Wuenschell GE; Shuck SC; Ciminera AK; De Jesus LR; Ouyang C; Chen MY; Termini J
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385725
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
12. Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies.
William D; Mullins CS; Schneider B; Orthmann A; Lamp N; Krohn M; Hoffmann A; Classen CF; Linnebacher M
J Transl Med; 2017 Feb; 15(1):27. PubMed ID: 28183348
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.
Zakaria Z; Tivnan A; Flanagan L; Murray DW; Salvucci M; Stringer BW; Day BW; Boyd AW; Kögel D; Rehm M; O'Brien DF; Byrne AT; Prehn JH
Br J Cancer; 2016 Jan; 114(2):188-98. PubMed ID: 26657652
[TBL] [Abstract][Full Text] [Related]
14. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
15. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma.
Crommentuijn MH; Maguire CA; Niers JM; Vandertop WP; Badr CE; Würdinger T; Tannous BA
Mol Oncol; 2016 Apr; 10(4):625-34. PubMed ID: 26708508
[TBL] [Abstract][Full Text] [Related]
16. EGFR gene overexpression retained in an invasive xenograft model by solid orthotopic transplantation of human glioblastoma multiforme into nude mice.
Yi D; Hua TX; Lin HY
Cancer Invest; 2011 Mar; 29(3):229-39. PubMed ID: 21314332
[TBL] [Abstract][Full Text] [Related]
17. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.
Candolfi M; Curtin JF; Nichols WS; Muhammad AG; King GD; Pluhar GE; McNiel EA; Ohlfest JR; Freese AB; Moore PF; Lerner J; Lowenstein PR; Castro MG
J Neurooncol; 2007 Nov; 85(2):133-48. PubMed ID: 17874037
[TBL] [Abstract][Full Text] [Related]
18. Orthotopic Patient-Derived Glioblastoma Xenografts in Mice.
Xu Z; Kader M; Sen R; Placantonakis DG
Methods Mol Biol; 2018; 1741():183-190. PubMed ID: 29392700
[TBL] [Abstract][Full Text] [Related]
19. An orthotopic glioblastoma animal model suitable for high-throughput screenings.
Pudelko L; Edwards S; Balan M; Nyqvist D; Al-Saadi J; Dittmer J; Almlöf I; Helleday T; Bräutigam L
Neuro Oncol; 2018 Oct; 20(11):1475-1484. PubMed ID: 29750281
[TBL] [Abstract][Full Text] [Related]
20. Implantation of GL261 neurospheres into C57/BL6 mice: a more reliable syngeneic graft model for research on glioma-initiating cells.
Yi L; Zhou C; Wang B; Chen T; Xu M; Xu L; Feng H
Int J Oncol; 2013 Aug; 43(2):477-84. PubMed ID: 23708048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
